Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. (ACRS) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · ACRS · as of Jun 9, 2026
Activity summary
Buy transactions
0
P-Purchase only
Sell transactions
0
12 Months
Buy/Sell ratio
0.00
Buy/Sell (by trades)
Overall sentiment
Aclaris Therapeutics, Inc. insiders have shown mixed buying and selling activity over the past 12 Months.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 9, 2026
ACRS insider buying and selling by quarter
ACRS insider selling · ACRS insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 9, 2026
Active insiders
Most active in past 12 months · ACRS ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
ACRS executive sell shares · ACRS board member insider trading · ACRS insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Jun 5, 2026 | Mehra Anand Director | Option | 11,580 | — | Form 4 |
| Jun 5, 2026 | SCHIFF ANDREW N Director | Option | 11,580 | — | Form 4 |
| Jun 5, 2026 | Molineaux Christopher P. Director | Option | 11,580 | — | Form 4 |
| Jun 5, 2026 | Humphries William D. Director | Option | 11,580 | — | Form 4 |
| Jun 5, 2026 | MILANO VINCENT Director | Option | 11,580 | — | Form 4 |
| Jun 5, 2026 | GOWEN MAXINE Director | Option | 11,580 | — | Form 4 |
| May 1, 2026 | Hall Jesse Wayne Chief Medical Officer | Option | 36,375 | — | Form 4 |
| May 1, 2026 | Hall Jesse Wayne Chief Medical Officer | Other | 9,330 | $41K | Form 4 |
| Apr 23, 2026 | Leonard Braden Michael 10 percent owner | Sale | 300,000 | $1.36M⚡ | Form 4 |
| Mar 1, 2026 | Balthaser Kevin CFO | Option | 2,375 | — | Form 4 |
| Mar 1, 2026 | Balthaser Kevin CFO | Other | 677 | $2K | Form 4 |
| Feb 3, 2026 | Loerop James Chief Business Officer | Option | 20,875 | — | Form 4 |
| Feb 3, 2026 | Loerop James Chief Business Officer | Other | 5,937 | $21K | Form 4 |
| Feb 3, 2026 | Walker Neal CEO · Director | Option | 63,475 | — | Form 4 |
| Feb 3, 2026 | Walker Neal CEO · Director | Other | 18,611 | $65K | Form 4 |
| Feb 3, 2026 | Davis Hugh M. President and COO · Director | Option | 18,675 | — | Form 4 |
| Feb 3, 2026 | Balthaser Kevin CFO | Option | 22,025 | — | Form 4 |
| Feb 3, 2026 | Balthaser Kevin CFO | Other | 6,449 | $22K | Form 4 |
| Feb 1, 2026 | Balthaser Kevin CFO | Option | 14,750 | — | Form 4 |
| Feb 1, 2026 | Balthaser Kevin CFO | Other | 4,984 | $17K | Form 4 |
| Jan 2, 2026 | Walker Neal CEO · Director | Option | 29,150 | — | Form 4 |
| Jan 2, 2026 | Walker Neal CEO · Director | Other | 9,952 | $29K | Form 4 |
| Dec 31, 2025 | Loerop James Chief Business Officer | Option | 73,750 | — | Form 4 |
| Jan 2, 2026 | Loerop James Chief Business Officer | Option | 18,150 | — | Form 4 |
| Jan 2, 2026 | Loerop James Chief Business Officer | Other | 6,171 | $18K | Form 4 |
Hall Jesse Wayne
Chief Medical Officer
Date
May 1
Shares
9,330
Price
$4.41
Value
$41K
Leonard Braden Michael
10 percent owner
Date
Apr 23
Shares
300,000
Price
$4.53
Value
$1.36M ⚡
Loerop James
Chief Business Officer
Date
Feb 3
Shares
5,937
Price
$3.47
Value
$21K
Davis Hugh M.
President and COO · Director
Date
Feb 3
Shares
18,675
Price
—
Value
—
Loerop James
Chief Business Officer
Date
Jan 2
Shares
6,171
Price
$2.88
Value
$18K
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About ACRS insider trading
ACRS insider trades
Aclaris Therapeutics, Inc. (ACRS) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Balthaser Kevin (CFO), Loerop James (Chief Business Officer), Walker Neal (CEO · Director). Over the past 12 months, 5 insiders have filed transactions with the SEC. ACRS insiders have been mixed buying and selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Aclaris Therapeutics, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
ACRS insider trading · 5 questionsThe insiders of Aclaris Therapeutics, Inc. (ACRS) include executives and directors such as Balthaser Kevin (CFO), Loerop James (Chief Business Officer), Walker Neal (CEO · Director), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 9, 2026